EUCTR2014-005320-10-FR进行中（未招募）1 期
on-randomised Open Label Pilot Study of Sirolimus Therapy for Segmental Overgrowth Due to PIK3CA- Related Overgrowth
CHU de DIJO0 个研究点开始时间: 2015年6月29日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
已完成
2 期
An open label phase II study of Sirolimus in patients with segmental overgrowth syndromeSEGMENTAL OVERGROWTH SYNDROMEQ85.8Q87.8Q87.3Other phakomatoses, not elsewhere classifiedOther specified congenital malformation syndromes, not elsewhere classifiedCongenital malformation syndromes involving early overgrowthDRKS00010085niversitätsklinikum Freiburg18
进行中（未招募）
1 期
Studie zu Sirolimus bei Patienten mit ÜberwuchssyndromSegmental overgrowth syndromeEUCTR2015-005416-15-DEMedical Center - University of Freiburg18
已完成
3 期
An open-label continuation trial of sirolimus for tocilizumab-refractory idiopathic multicentric Castleman's disease: Study protocol for an investigator-initiated, multicenter, open-label trial (SPIRIT Compliant)JPRN-jRCT2051200050Kawakami Atsushi20
进行中（未招募）
1 期
Sirolimus treatment for segmental overgrowthEUCTR2014-000484-41-GBCambridge University Hospitals NHS Foundation Trust and the University of Cambridge11
已完成
不适用
Clinical study on efficacy and safety of sirolimus against epileptic seizures of focal cortical dysplasia type IIPatients with epilepsy with focal cortical dysplasia type 2JPRN-UMIN000030962Hokkaido University Hospital2